文献速递泌尿生殖与妇科肿瘤放疗

澳大利亚前列腺癌患者接受外照射放疗时近距离放疗推量的真实世界应用及患者报告功能结局

Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-08-19

基于维多利亚州前列腺癌结局登记处的1,626例局限性前列腺癌患者队列,2015至2020年间接受外照射放疗者中88例(5.4%)接受了近距离放疗推量。1,555例完成EPIC-26问卷,12个月时外照射加近距离推量组与外照射单独组在泌尿、性和肠道功能域评分上无统计学或临床显著差异。

要点

  • 1,626例接受外照射放疗的前列腺癌患者中88例(5.4%)接受了近距离放疗推量。
  • 近距离放疗推量独立相关因素为较年轻年龄、较高社会经济地位和公立机构治疗。
  • 12个月时外照射加推量组与单独外照射组EPIC-26各功能域评分无统计学或临床显著差异。

核心结论

  • 接受外照射放疗的前列腺癌患者中每20例有1例接受近距离放疗推量。
  • 这是澳大利亚首次在人群水平报告外照射加或不加近距离推量后的患者报告功能结局,无证据提示加用近距离推量后12个月功能结局更差。

研究设计与样本

  • 基于人群的队列研究,纳入维多利亚州前列腺癌结局登记处2015至2020年间接受外照射放疗的局限性前列腺癌男性。
  • 主要结局为接受近距离放疗推量的比例及治疗后12个月采用EPIC-26问卷评估的患者报告功能结局。
  • 采用多变量逻辑回归评估与近距离放疗推量相关的因素,采用线性回归估计外照射单独与外照射加近距离推量之间EPIC-26各功能域评分的差异。

主要发现

  • 1,626例患者中88例(5.4%)接受了近距离放疗推量。
  • 与近距离放疗推量独立相关的因素为较年轻年龄、较高社会经济地位和在公立机构治疗。
  • 1,555例完成了EPIC-26问卷。
  • 外照射加近距离推量组与单独外照射组相比,EPIC-26尿失禁、尿刺激/梗阻、性和肠道功能域评分的调整平均差异分别为1.28(95%CI=-3.23至5.79)、-2.87(95%CI=-6.46至0.73)、0.49(95%CI=-4.78至5.76)和2.89(95%CI=-0.83至6.61),无统计学或临床显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We aimed to evaluate utilisation of brachytherapy (BT) boost in men who had external beam radiation therapy (EBRT) for prostate cancer, and to compare patient-reported functional outcomes (PRO) following each approach in a population-based setting in Australia. MATERIALS AND METHODS: This is a population-based cohort of men with localised prostate cancer enrolled in the Victorian Prostate Cancer Outcomes Registry, who had EBRT between 2015 and 2020. Primary outcomes were proportion who had BT-boost, and PRO (assessed using the EPIC-26 questionnaires) 12 months post-treatment. Multivariable logistic regressions were used to evaluate factors associated with BT-boost, and linear regressions were used to estimate differences in EPIC-26 domain scores between EBRT alone and EBRT + BT. RESULTS: Of the 1,626 men in the study, 88 (5.4 %) had BT-boost. Factors independently associated with BT-boost were younger age, higher socioeconomic status, and treatment in public institutions. 1,555 men completed EPIC-26 questionnaires. No statistically or clinically significant differences in EPIC-26 urinary, sexual and bowel functional domain scores were observed between men who had EBRT + BT vs EBRT alone, with adjusted mean differences in urinary incontinence, urinary irritative/ obstruction, sexual, and bowel domain of 1.28 (95 %CI = -3.23 to 5.79), -2.87 (95 %CI = -6.46 to 0.73), 0.49 (95 %CI = -4.78 to 5.76), and 2.89 (95 %CI = -0.83 to 6.61) respectively. CONCLUSION: 1-in-20 men who had EBRT for prostate cancer had BT-boost. This is the first time that PRO following EBRT+/-BT is reported at a population-based level in Australia, with no evidence to suggest worse PRO with addition of BT-boost 12 months post-treatment.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ong WL, Evans M, Papa N, et al. Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia. Clin Transl Radiat Oncol. 2022. PMID: 36052020. doi:10.1016/j.ctro.2022.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。